Medline ® Abstract for Reference 108
of 'Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects'
Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.
Park SG, Chung CH, Park CY
There are no effective conventional systemic cytotoxic therapies for patients with unresectable or advanced hepatocellar carcinoma (HCC). Sorafenib, an oral multi-targeted tyrosine kinase inhibitor, was recently approved for the treatment of patients with HCC. Sorafenib is generally well tolerated and has an acceptable toxicity profile.Gastrointestinal perforation is a rare adverse event. We present a case of transverse colon perforation during sorafenib therapy for advanced HCC. A 68-year-old woman with advanced HCC was treated with sorafenib. Eight weeks later the patient presented with the sudden onset of sharp abdominal pain. Emergency surgery was performed for panperitonitis and a perforation involving the transverse colon.
Department of Internal Medicine, Hemato-oncology, Chosun University Hospital, Gwangju, Republic of Korea.